Type 2 Diabetes And Obesity Research - ZenBio, Inc. Awarded $1.38 Million Phase II SBIR Grant For Skeletal Muscle Program
Oct 3rd 2008Drug InformationDiabetes
ZenBio, Inc. announced that it has been awarded a Phase II SBIR grant to commercialize their primary human skeletal myocyte and adipocyte co-culture system. The $1.38 million award from the National Institutes of Health will fund the continued optimization and commercial development of this unique tool for type 2 diabetes and obesity research.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.